Session: SUN 432-458-Thyroid Autoimmunity
Poster Board SUN-440
Materials and Methods: The review board approved this study. 34 patients with Graves’ disease treated with thyroid arterial embolization during 1997 and 2009 were followed for a median of 11.5 years. Symptoms and signs of hyperthyroidism, levels of thyroid hormones and thyroid-stimulating hormone (TSH), size and blood flow of the thyroid, immunological status, and complications were monitored.
Results: 34 patients were followed for a median of 11.5 years. 17 of 34 patients (50%) achieved euthyroid status within 2 months after the procedure, among which 4 had a recurrence (23.5%) at 11, 42, 50 and 106 months after embolization. The remaining 17 (50%) patients had partial response to the procedure and required additional treatments to maintain a euthyroid state. Patients embolized with smaller granules of polyvinyl alcohol (PVA) had a higher cure rate (P<0.05). Those who had 3 arteries embolized had a trend of achieving better response. Patients with a shorter duration of hyperthyroidism before embolization had a higher cure rate (P<0.05). Patients with higher levels of thyroglobulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) before embolization had a lower risk of recurrence (P=0.008 and P=0.001, respectively). No serious complications or exacerbation of Graves’ ophthalmopathy occurred after the procedure.When the levels of TRAb and CD19+CD5- lymphocytes were correlated with the thyroid function, there was a significant difference between euthyroid and hyperthyroid patients.
Conclusion: Thyroid arterial embolization is a minimally invasive and safe alternative approach for the treatment of Graves’ disease with good long-term outcomes.
Nothing to Disclose: YL, HX
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters